Magdalene Moran
President and Chief Scientific Officer, Caraway Therapeutics

Leading Research at a Biotechnology Company

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. Dr. Moran is leading scientific research into the discovery and early development of pharmaceuticals in multiple disease areas. She is a noted expert on ion channels, especially the Transient Receptor Potential (TRP) superfamily.  She was the first employee of the company.

Prior to joining Caraway Therapeutics, Dr. Moran was the Senior Vice President of biology at Hydra Biosciences, where she was part of the scientific team for over 15 years. She led discovery and early development projects in pain, pulmonary, CNS, and renal diseases, resulting in six clinical candidates in six years. In addition, Dr. Moran was the scientific representative for business development activities and coordinated the scientific advisory and medical advisory boards. Before Hydra, Dr. Moran served as a graduate student in the laboratory of ion channel expert Dr. David Clapham at Children’s Hospital in Boston, where she studied the basal transcription machinery and cloned several novel ion channels.  She received her PhD in Neurobiology from the Program in Neuroscience at Harvard University.

In this HBI career chat, Dr. Moran will discuss working in industry, some of the differences from academia, and provide a brief survey of some of the different types of roles required for a biotech company.

Open to all Harvard students, fellows, faculty, and staff
Questions? Email us at info@dev-harvard-brain-science-initiative.pantheonsite.io//hbi.